Clinical trials: Exercise Therapy
Pulmonary Arterial Hypertension
Assessing the Utility of Submaximal CPET in Treatment Management of PAH
Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality.
- Trial name
- NCT05977933
- Testing
- Shape II CPET
- Where
- 6 sites in United States
- Volunteers
- 550 people
- Sponsor
- Shape Medical Systems, Inc.
Glucose Intolerance
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using…
- Trial name
- NCT01405911
- Testing
- Sitagliptin 25 mg, Sitagliptin 50 mg
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Falls
A Digital Balance Program With Comparison Group
This research study evaluates a digital musculoskeletal care program specifically focused on balance improvement and falls prevention.
- Trial name
- NCT06868680
- Testing
- Balance Program, Educational Reading Content
- Where
- United States
- Volunteers
- 687 people
- Sponsor
- Hinge Health, Inc
Neck Pain
kINESIOTAPING ON PATIENT'S FUNCTIONAL STATUS IN NON-SPECIFIC NECK PAIN
The objective of the study is to find the effectiveness of kinesiotaping on the patient's functional status in non-specific neck pain.
- Trial name
- NCT04733248
- Testing
- Kinesiotaping group, stretching group
- Where
- Pakistan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Aqua Medical Services (Pvt) Ltd
Muscle Pain
Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise
Comparison of the effect of etoricoxib to placebo on muscle pain caused by eccentric contractions
- Trial name
- NCT01271348
- Testing
- Etoricoxib
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- X-pert Med GmbH
Mucopolysaccharidosis IVA, Morquio A Syndrome
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01609062
- Testing
- BMN 110
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- BioMarin Pharmaceutical
Migraine, Migraine With Aura
A Comprehensive Digital Care Program for Migraine Management
This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT07642414
- Testing
- Neuromodulation Wearable Device, Migraine Digital Care Program
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Hinge Health, Inc
Mild Traumatic Brain Injury, Concussion, Mild
Exercise as Concussion Therapy Trial- 2
This study is a Phase 2, open-label study of a therapeutic intervention (graded exercise)compared to a reference therapy (passive stretching) in patients who have sustained mTBI.
- Trial name
- ExACTT (NCT04578743)
- Testing
- Graded Exercise Therapy: ClearPlay(TM)
- Where
- 3 sites in Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- ANSwers Neuroscience, Inc.
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety…
- Trial name
- NCT07109700
- Testing
- HDM1005 1, HDM1005 2, HDM1005 3
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Pain, Physical Function
Digitally Delivered Exercise and Education Treatment for Low Back Pain: 3 Months Follow-up
Exercise and education is recommended as the first-line treatment by evidence-based, international guidelines for low back pain (LBP).
- Trial name
- Back3months (NCT05226156)
- Testing
- Digitally delivered exercise and education treatment Joint Academy
- Where
- Sweden
- Volunteers
- 2,593 people
- Sponsor
- Joint Academy
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01040793
- Testing
- Olodaterol (BI 1744), Olodaterol (BI1744)
- Where
- 19 sites in Austria, Belgium and 3 more
- Volunteers
- 157 people
- Sponsor
- Boehringer Ingelheim
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor for Home Exercise Performance Before and After Operation
Multicenter, Prospective, Randomized, Comparative Study Measuring the Effects on Clinical Outcomes, Patient Satisfaction, Costs and Benefits of Combined Pre-, Intra- and Postoperative Patient Data for THA and TKA Patients Using…
- Conditions
- Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Clinical Outcome, Patient Satisfaction
- Trial name
- ORTHOPATH (NCT05182320)
- Testing
- OrthoPath, Control
- Where
- 2 sites in Germany
- Sponsor
- Aesculap AG
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01040130
- Testing
- Olodaterol (BI 1744)
- Where
- 19 sites in Australia, Austria and 3 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
SARS-CoV-2 Infection, Lung Fibrosis
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
The innovative drug Treamid is planned for use in the treatment of patients with persistent lung damage and reduced exercise tolerance exertion after COVID-19 pneumonia in a multicenter, randomized, double-blind…
- Trial name
- NCT05516550
- Testing
- Treamid, Treamid twice a day, Treamid once a day
- Volunteers
- 412 people
- Sponsor
- PHARMENTERPRISES LLC
Injury Traumatic, Muscle Injury
Antigravity Treadmill With Alter G on the Postural Stability of Traumatic Lower Limb Injuries
This prospective randomised study aimed to test the investigators's hypothesis that anti-gravity treadmill therapy has beneficial effects on postural stability tests over a standard rehabilitation protocol in patients who have…
- Conditions
- Injury Traumatic, Muscle Injury, Bone Injuries Joints, Tendon Injuries
- Trial name
- ALTERG20 (NCT05285020)
- Testing
- Alter G, Parallel bars and Scale, Standard rehabilitation protocol
- Volunteers
- 30 people
- Sponsor
- FREMAP Mutual Insurance Company for Occupational Accidents and Diseases
Chronic Obstructive Pulmonary Disease
Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea
This observational non-interventional study is designed to demonstrate the improvement of physical function in COPD patients with exercise-induced dyspnoea on treatment with Spiriva (tiotropium 18 µg capsules) and allows adverse…
- Trial name
- NCT00540163
- Where
- 177 sites in Germany
- Volunteers
- 1,296 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Tumour Registry Colorectal Cancer
To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.
- Trial name
- TKK (NCT00910819)
- Where
- Germany
- Volunteers
- 7,000 people
- Sponsor
- iOMEDICO AG
Muscle Soreness
Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness
Multiple-dose, double-blind, double-dummy, parallel, randomized, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for muscle soreness from exercise.
- Trial name
- NCT00745771
- Testing
- Diractin
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- IDEA AG